Skip to content
10-Q

Quarterly Report

MELINTA THERAPEUTICS, INC. /NEW/

0001461993-19-000015

← back to feed
Filed
May 10, 2019 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2019 · Apr 26, 2019 11.78M sh
Capex Q1 2019 · Mar 31, 2019 $12K
Capex Q1 2019 · Mar 31, 2018 $504K
Operating Cash Flow Q1 2019 · Mar 31, 2019 −$37.32M
Operating Cash Flow Q1 2019 · Mar 31, 2018 −$51.42M
Cash And Equivalents Q1 2019 · Mar 31, 2019 $116.9M
Cash And Equivalents Q1 2019 · Dec 31, 2018 $81.81M
Stockholders Equity Q1 2019 · Mar 31, 2019 $176.52M
Stockholders Equity Q1 2019 · Dec 31, 2018 $190.06M
Stockholders Equity Q1 2019 · Mar 31, 2018 $199.83M
Stockholders Equity Q1 2019 · Dec 31, 2017 $72.34M
Current Liabilities Q1 2019 · Mar 31, 2019 $129.96M
Current Liabilities Q1 2019 · Dec 31, 2018 $133.61M
Total Liabilities Q1 2019 · Mar 31, 2019 $293.93M
Total Liabilities Q1 2019 · Dec 31, 2018 $251.53M
Current Assets Q1 2019 · Mar 31, 2019 $181.76M
Current Assets Q1 2019 · Dec 31, 2018 $149.48M
Total Assets Q1 2019 · Mar 31, 2019 $470.45M
Total Assets Q1 2019 · Dec 31, 2018 $441.59M
Sga Expense Q1 2019 · Mar 31, 2019 $25.94M
Sga Expense Q1 2019 · Mar 31, 2018 $34.62M
Rd Expense Q1 2019 · Mar 31, 2019 $5.36M
Rd Expense Q1 2019 · Mar 31, 2018 $16.13M
Net Income Q1 2019 · Mar 31, 2019 −$26.53M
Net Income Q1 2019 · Mar 31, 2018 −$29.43M
Operating Income Q1 2019 · Mar 31, 2019 −$24.59M
Operating Income Q1 2019 · Mar 31, 2018 −$43.6M
Cost Of Revenue Q1 2019 · Mar 31, 2019 $7.37M
Cost Of Revenue Q1 2019 · Mar 31, 2018 $7.69M
Revenue Q1 2019 · Mar 31, 2019 $14.08M
Revenue Q1 2019 · Mar 31, 2018 $14.84M